MEDICINOVA INC (MNOV) Stock News

USA - NASDAQ:MNOV - US58468P2065 - Common Stock

1.42 USD

+0.02 (+1.43%)

Last: 11/7/2025, 4:10:09 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MNOV Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill - Mentions: TGE AMTD RUBI MSPR ...

News Image

Unusual volume stocks in Monday's session

7 days ago - By: Chartmill - Mentions: TGE BFLY VVPR CABA ...

News Image

Which stocks are experiencing notable movement on Friday?

9 hours ago - By: Benzinga - Mentions: TNDM CDXS GMED WORX ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

a day ago - By: MediciNova, Inc.

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

a day ago - By: MediciNova, Inc.

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

3 days ago - By: MediciNova, Inc.

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

7 days ago - By: Benzinga - Mentions: INTS KALA EDSA PHGE ...

12 Health Care Stocks Moving In Friday's After-Market Session

7 days ago - By: Chartmill - Mentions: HBIO TACO WKEY ADTX ...

News Image

These stocks have an unusual volume in today's session

8 days ago - By: Stocktwits

News Image

MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’

8 days ago - By: MediciNova, Inc.

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

8 days ago - By: MediciNova, Inc.

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

a month ago - By: MediciNova, Inc.

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

a month ago - By: MediciNova, Inc.

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

2 months ago - By: MediciNova, Inc.

MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)

2 months ago - By: MediciNova, Inc.

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

2 months ago - By: MediciNova, Inc.

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

2 months ago - By: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

2 months ago - By: MediciNova, Inc.

MediciNova Provides Shareholder Update on Key Developments

2 months ago - By: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: MediciNova, Inc.

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

2 months ago - By: MediciNova, Inc.

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

3 months ago - By: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

3 months ago - By: MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

4 months ago - By: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

4 months ago - By: MediciNova, Inc.

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

7 months ago - By: MediciNova, Inc.

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

7 months ago - By: MediciNova, Inc.

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

7 months ago - By: MediciNova, Inc.

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

7 months ago - By: MediciNova, Inc.

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

a year ago - By: MediciNova, Inc.

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

a year ago - By: MediciNova, Inc.

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

a year ago - By: MediciNova, Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

a year ago - By: MediciNova, Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

a year ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

a year ago - By: MediciNova, Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

a year ago - By: MediciNova, Inc.

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis